Why Merck Missed the Mark
Why Merck Missed the Mark S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report […]
Why Merck Missed the Mark S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report […]
Biotech: Teva’s Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market
Biotech: Teva’s Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market
Gene Therapy Rebuilds Gums Gene therapy can restore damage caused by severe gum disease, suggest animal studies.
Is Viagra Vulnerable? Eli Lilly’s Cialis lasts for 36 hours–and a $100 million ad blitz will spread the word
It’s Wake-Up Time Kiss your pillow good-bye. A new breed of drugs promises to do for drowsiness what Prozac did
It’s Wake-Up Time Kiss your pillow good-bye. A new breed of drugs promises to do for drowsiness what Prozac did
Biotech plans: Boon or fantasy? Having mapped hormones, synthesized molecules and discovered new cell receptors, the Scripps Research Institute wants
REDISCOVERING NATURAL PRODUCTS Cast aside for years, natural products drug discovery appears to be reclaiming attention and on the verge
Biotech funding on track to bounce back It’s not over yet, but 2003 already looks like a banner year for
Get new actionable insights and updates from BiotechBlog